Senti Biosciences, Inc. (NASDAQ:SNTI) Short Interest Down 38.7% in December

Senti Biosciences, Inc. (NASDAQ:SNTI) saw a large decline in short interest in the month of December. As of December 31st, there was short interest totaling 1,019,881 shares, a decline of 38.7% from the December 15th total of 1,663,760 shares. Currently, 4.0% of the company’s shares are short sold. Based on an average daily volume of 511,420 shares, the days-to-cover ratio is presently 2.0 days. Based on an average daily volume of 511,420 shares, the days-to-cover ratio is presently 2.0 days. Currently, 4.0% of the company’s shares are short sold.

Institutional Trading of Senti Biosciences

A number of hedge funds and other institutional investors have recently made changes to their positions in SNTI. Citadel Advisors LLC bought a new position in shares of Senti Biosciences during the 3rd quarter valued at about $117,000. Geode Capital Management LLC grew its position in Senti Biosciences by 395.6% during the second quarter. Geode Capital Management LLC now owns 147,314 shares of the company’s stock valued at $311,000 after acquiring an additional 117,588 shares during the last quarter. Finally, Armistice Capital LLC purchased a new position in shares of Senti Biosciences during the second quarter worth approximately $1,883,000. 25.70% of the stock is currently owned by institutional investors.

Senti Biosciences Price Performance

Shares of NASDAQ SNTI traded down $0.03 during midday trading on Friday, reaching $1.03. The company’s stock had a trading volume of 177,179 shares, compared to its average volume of 325,040. The firm has a 50 day moving average price of $1.50 and a 200-day moving average price of $1.67. Senti Biosciences has a 12-month low of $1.03 and a 12-month high of $5.10.

Senti Biosciences (NASDAQ:SNTI) last posted its quarterly earnings data on Thursday, November 13th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.10). On average, equities analysts anticipate that Senti Biosciences will post -14.54 EPS for the current year.

Analyst Upgrades and Downgrades

SNTI has been the subject of several recent analyst reports. HC Wainwright assumed coverage on shares of Senti Biosciences in a research report on Tuesday, October 14th. They set a “buy” rating and a $12.00 price objective for the company. Leerink Partners assumed coverage on shares of Senti Biosciences in a report on Friday, November 21st. They set an “outperform” rating and a $6.00 price objective on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Senti Biosciences in a research note on Wednesday, October 8th. Leerink Partnrs raised Senti Biosciences to a “strong-buy” rating in a research note on Friday, November 21st. Finally, Chardan Capital raised their price objective on Senti Biosciences from $12.00 to $13.00 and gave the company a “buy” rating in a research note on Tuesday, December 9th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Senti Biosciences currently has a consensus rating of “Moderate Buy” and an average price target of $9.00.

About Senti Biosciences

Senti Biosciences (NASDAQ:SNTI) is a clinical-stage synthetic biology company focused on engineering next-generation cell therapies. The company’s platform leverages modular genetic circuits to sense disease signals and precisely control cellular functions, with the goal of improving safety and efficacy in oncology and immune-mediated diseases.

Senti’s core technologies include its SENTINEL circuit platform and SNIP receptor system, which enable programmable sensing of molecular cues and context-dependent payload release.